Update on the management and treatment of viral hepatitis

• Published in: World journal of gastroenterology : WJG Vol. 27; no. 23; pp. 3249 - 3261
• Main Authors: Almeida, Patricia Holanda, Matielo, Celso E L, Curvelo, Lilian A, Rocco, Rodrigo A, Felga, Guilherme, Della Guardia, Bianca, Boteon, Yuri L
• Format: Journal Article
• Language: English
• Published: Baishideng Publishing Group Inc 21.06.2021
• Subjects: Minireviews
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.v27.i23.3249

This review aims to summarize the current evidence on the treatment of viral hepatitis, focusing on its clinical management. Also, future treatment options and areas of potential research interest are detailed. PubMed and Scopus databases were searched for primary studies published within the last ten years. Keywords included hepatitis A virus, hepatitis B virus (HBV), hepatitis C virus, hepatitis D virus (HDV), hepatitis E virus, and treatment. Outcomes reported in the studies were summarized, tabulated, and synthesized. Significant advances in viral hepatitis treatment were accomplished, such as the advent of curative therapies for hepatitis C and the development and improvement of hepatitis A, hepatitis B, and hepatitis E vaccination. Drugs that cure hepatitis B, going beyond viral suppression, are so far unavailable; however, targeted antiviral drugs against HBV (immunomodulatory therapies and gene silencing technologies) are promising approaches to eradicating the virus. Ultimately, high vaccination coverage and large-scale test-and-treat programmes with high screening rates may eliminate viral hepatitis and mitigate their burden on health systems. The development of curative hepatitis C treatment renewed the enthusiasm for curing hepatitis B, albeit further investigation is required. Novel therapeutic options targeting HDV life cycle are currently under clinical investigation.